Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CLN.WA
HoldFallen FavouriteCelon Pharma S.A. · Healthcare · Poland · $231M · Avg Vol: $96K/d
COMPANY DESCRIPTION
Celon Pharma S.A. is an integrated Polish biopharmaceutical company engaged in the research, development, and manufacturing of generic and innovative drugs, particularly in oncology, neurology, and inflammatory diseases. The company possesses advanced R&D laboratories and a modern manufacturing facility, allowing it to control the entire drug development lifecycle. Its competitive moat is anchored by a robust pipeline of proprietary molecules and a strong market share in inhalation drugs.
FINANCIAL SUMMARY (PLN)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 169.6M | 161.9M | 164.4M | 177.5M | — | 1.5% | 254.4M | 293.8M | 288.7M | 17.6% |
| EPS (PLN) | — | -0.77 | -0.55 | -0.64 | -1.49 | — | 2.04 | — | — | — |
| Shares | — | 51.0M | 51.1M | 53.9M | 53.9M | +5.5% | — | — | — | — |
| Debt | 14.9M | 26.8M | 25.6M | 16.9M | — | 4.3% | 53.7M | — | — | — |
| Equity | — | 479.6M | 445.6M | 445.2M | 363.2M | -8.8% | — | — | — | — |
| Op CF | — | -4.7M | -8.3M | -11.3M | 23.9M | — | 30.5M | — | — | — |
| Inv CF | — | -31.5M | -21.6M | -7.5M | -21.6M | — | — | — | — | — |
| Fin CF | — | -28.7M | -20.6M | 13.3M | -9.8M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CLN.WA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CLN.WA | Celon Pharma S.A.(you) | $231M | 46 | Hold |
| SLV.WA | Selvita S.A. | $132M | 40 | Hold |
| ICE.WA | Medinice S.A. | $200M | 25 | Sell |
| BIO.WA | BIOTON S.A. | $87M | 51 | Hold |
| MRC.WA | Mercator Medical S.A. | $143M | 73 | Buy |
| BCX.WA | Bioceltix S.A. | $118M | 18 | Strong Sell |
| SNT.WA | Synektik Spólka Akcyjna | $763M | 64 | Hold |
| SCP.WA | Scope Fluidics S.A. | $116M | 11 | Strong Sell |
| VOX.WA | Voxel S.A. | $374M | 88 | Strong Buy |
| MDG.WA | Medicalgorithmics S.A. | $75M | 16 | Strong Sell |
Peer medians: ROE -19.0% · P/E 18.1x · Gross margin 30.1%